Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 6—June 2013
Synopsis

New Delhi Metallo-β-Lactamase–producing Enterobacteriaceae, United States

J. Kamile RasheedComments to Author , Brandon Kitchel, Wenming Zhu, Karen F. Anderson, Nancye C. Clark, Mary Jane Ferraro, Patrice Savard, Romney M. Humphries, Alexander J. Kallen, and Brandi M. Limbago
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.K. Rasheed, B. Kitchel, W. Zhu, K.F. Anderson, N.C. Clark, A.J. Kallen, B.M. Limbago); Massachusetts General Hospital, Boston, Massachusetts, USA (M.J. Ferraro); Johns Hopkins University, Baltimore, Maryland, USA (P. Savard); Johns Hopkins Health System, Baltimore (P. Savard); University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA (R.M. Humphries)

Main Article

Table 3

Antimicrobial drug susceptibility profiles of NDM-producing isolates collected and Escherichia coli transformants, United States, April 2009–March 2011*

Isolate no. Organism MIC, µg/mL

Broth microdilution MBL screen result

Modified Hodge test result
TGC SXT CTX FEP ATM DOR ETP MER IMP IMP+EP† Ratio MBL ETP/MER
0S-506 Klebsiella pneumoniae ≤0.5 >8 >64 >32 >64 >8 >4 >8 >32 1 ≥64 + –/–
1100770 K. pneumoniae 2 >8 >64 >32 >64 >8 >4 >8 32 0.5 64 + +/–
1100975 K. pneumoniae 2 >8 >64 >32 >64 >8 >4 >8 32 1 32 + +/+
1100192 K. pneumoniae 1 >8 >64 >32 >64 >8 >4 >8 8 ≤0.5 ≥16 + +/–
1000527 K. pneumoniae >4 >8 >64 >32 >64 >8 >4 >8 >32 ≤0.5 >64 + +/+
1101459
K. pneumoniae
2
>8
>64
>32
>64
>8
>4
8
16

≤0.5
≥32
+

+/+
1101168
Salmonella enterica serovar Senftenberg
1
0.5
>64
>32
>64
8
>4
8
4

≤0.5
≥8
+

+/+
1100101 E. coli ≤0.5 >8 >64 >32 >64 >8 >4 >8 16 1 16 + +/–
1001728
E. coli
≤0.5
>8
>64
>32
16
>8
>4
>8
8

≤0.5
≥16
+

+/+
1000654
Enterobacter cloacae
>4
>8
>64
>32
>64
>8
>4
>8
>32

4
>8
+

+/+
0S-506 TF ≤0.5 ≤0.25 >64 16 64 4 4 4 4 ≤0.5 ≥8 + +/+
1100770 TF ≤0.5 ≤0.25 >64 32 32 4 8 4 4 ≤0.5 ≥8 + +/–
1100975 TF ≤0.5 ≤0.25 >64 16 32 4 4 4 2 ≤0.5 ≥4 + +/–
1100192 TF ≤0.5 ≤0.25 >64 16 ≤2 2 2 1 2 ≤0.5 ≥4 + +/+
1000527 TF ≤0.5 ≤0.25 >64 32 8 8 8 8 4 ≤0.5 ≥8 + +/+
1101459 TF ≤0.5 ≤0.25 >64 16 ≤2 4 4 4 4 ≤0.5 ≥8 + +/+
1101168 TF ≤0.5 ≤0.25 >64 16 ≤2 8 >8 8 8 ≤0.5 ≥16 + +/+
1100101 TF ≤0.5 ≤0.25 >64 >32 >64 >8 >8 16 8 ≤0.5 ≥16 + +/+
1001728 TF ≤0.5 ≤0.25 >64 32 32 8 8 8 8 ≤0.5 ≥16 + –/+
1000654
TF
≤0.5
>8
>64
>32
>64
>8
>8
32
32

≤0.5
≥64
+

+/+
Recipient E. coli DH-10BT1 ≤0.5 ≤0.25 ≤0.12 ≤0.5 ≤2 ≤0.12 ≤0.12 ≤0.12 ≤0.5 ≤0.5 ≤1 –/–

*NDM, New Delhi metallo-β-lactamase; ID, identification; MBL, Ambler class B metallo-β-lactamase; TGC, tigecycline; SXT, trimethoprim/sulfamethoxazole; CTX, cefotaxime; FEP, cefepime; ATM, aztreonam; DOR, doripenem; ETP, ertapenem; MER, meropenem; IMP, imipenem; EP, chelator; TF, transformant.
†IMP + EDTA + 1,10-phenanthroline, μg/mL.

Main Article

Page created: May 20, 2013
Page updated: May 20, 2013
Page reviewed: May 20, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external